Therapeutic angiogenesis for myocardial ischemia

Expert Review of Cardiovascular Therapy

Volumn 2, Issue 2, 2004, Pages 271-283

  Rosinberg, Audrey ^a   Khan, Tanveer A ^a   Sellke, Frank W ^a   Laham, Roger J ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Cell therapy; FGF gene therapy; Stem cells; VEGF

Indexed keywords

ADENOVIRUS VECTOR; ANGIOGENIC FACTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; GLYCERYL TRINITRATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LIPOSOME; NAKED DNA; NITRIC ACID DERIVATIVE; PLACEBO; PLASMID DNA; VASCULOTROPIN;

ADOPTIVE IMMUNOTHERAPY; ANGINA PECTORIS; ATHEROSCLEROSIS; CELL TYPE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED CANCER; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EMBRYO CELL; ENDOTHELIUM LESION; EXTRACELLULAR MATRIX; FEASIBILITY STUDY; GENE THERAPY; GENE TRANSFER; HEART ARREST; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEART PERFUSION; HEMATOPOIETIC STEM CELL; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FAILURE; MEMBRANOUS GLOMERULONEPHRITIS; MESENCHYME CELL; MICROCAPSULE; MYOBLAST; NONHUMAN; PNEUMONIA; PROLIFERATIVE RETINOPATHY; PROTEINURIA; REVIEW; SLOW RELEASE FORMULATION; VIRAL GENE DELIVERY SYSTEM;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; COLLATERAL CIRCULATION; CORONARY VESSELS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; MYOCARDIAL ISCHEMIA; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 2542601410     PISSN: 14779072     EISSN: None     Source Type: Journal    
DOI: 10.1586/14779072.2.2.271     Document Type: Review

References (105)

1. Rosamond WD, Chambless LE, Folsom AR et al. Trends in the incidence of myocardial infarction and in mortality due to coronary heart disease, 1987-1994. N. Engl. J. Med. 339, 861-867 (1998).
2. American Heart Association. Heart Disease and Stroke Statistics - 2003 Update. Dallas, TX, USA. American Heart Association (2002).
3. McNeer JF, Conley MJ, Sarmer CF et al. Complete and incomplete revascularization at aortocoronary bypass surgery: experience with 392 consecutive patients. Am. Heart J. 88(2), 176-182 (1974).
4. Levin DC, Beckman CF, Sos TA, Sniderman K. Incomplete myocardial reperfusion despite coronary artery bypass: a generally unrecognized shortcoming of the surgical approach to coronary artery disease. Radiology 142, 317-321 (1982).
5. Mukherjee D, Bhatt DL, Roe MT, Patel V, Ellis SG. Direct myocardial revascularization and angiogenesis - how many patients might be eligible? Am. J. Cardiol. 84, 598-600 (1999).
6. Jones EL, Weintraub WS. The importance of revascularization during long-term follow-up after coronary artery operations. J. Thorac. Cardiovasc. Surg. 112(2), 227-237 (1996).
7. Laham R, Simons M. Growth factor therapy in ischemic heart disease. In: Angiogenesis in Health and Disease. Rubanyi G (Ed.). Marcel Decker, NY, USA, 451-475 (2000).
8. Asahara T, Takahashi T, Masuda H et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J. 18(14), 3964-3972 (1999).
9. Tofukuji M, Metais C, Li J, Franklin A, Simons M, Sellke FW. Myocardial VEGF expression after cardiopulmonary bypass and cardioplegia. Circulation 98(Suppl. 19), 242-246 (1998).
10. Harada K, Friedman M, Lopez JJ et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am. J. Physiol. 270, H1791-H1802 (1996).
11. Banai S, Jaklitsch MT, Shou M et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89(5), 2183-2189 (1994).
12. Lopez JJ, Laham RJ, Stamler A et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc. Res. 40(2), 272-281 (1998).
13. Lopez JJ, Laham RJ, Carrozza JP et al. Hemodynamic effects of intracoronary VEGF delivery: evidence of tachyphylaxis and NO dependence of response. Am. J. Physiol. 273, H1317-H1323 (1997).
14. Celletti FL, Waugh JM, Amabile PG et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat. Med. 7(4), 425-429 (2001).
15. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1(1), 27-31 (1995).
16. Post MJ, Laham R, Sellke FW, Simons M. Therapeutic angiogenesis in cardiology using protein formulations. Cardiovasc. Res. 49(3), 522-531 (2001).
17. Faham S et al. Heparin structure and interactions with basic fibroblast growth factor. Science 271 (5252), 1116-1120 (1996).
18. Casscells W, Speir E, Sasse J et al. Isolation, characterization and localization of heparin-binding growth factors in the heart. J. Clin. Invest. 85(2), 433-441 (1990).
19. Bernotat-Danielowski S, Sharma HS, Schott RJ, Schaper W. Generation and localisation of monoclonal antibodies against fibroblast growth factors in ischaemic collateralised porcine myocardium. Cardiovasc. Res. 27(7), 1220-1228 (1993).
20. Schneider H, Huse K. Arterial gene therapy. Lancet 348(9038), 1380-1381 (1996).
21. Slavin J. Fibroblast growth factors: at the heart of angiogenesis. Cell Biol. Int. 19, 431-434 (1995).
22. Cuevas P, Carceller F, Ortega S et al. Hypotensive activity of fibroblast growth factor. Science 254, 1208-1210 (1991).
23. Sellke FW, Wang SY, Friedman M et al. Basic FGF enhances endothelium dependent relaxation of collateral perfused microcirculation. Am. J. Physiol. 267, H1303-H1311 (1994).
24. Battler A, Scheinowitz M, Bor A et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J. Am. Coll. Cardiol. 22(7), 2001-2006 (1993).
25. Yanagisawa-Miwa A, Uchida Y, Nakamura F et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 257(5075), 1401-1403 (1992).
26. Laham RJ, Rezaee M, Post M et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J. Pharmacol. Exp. Ther. 292(2), 795-802 (2000).
27. Harada K, Grossman W, Friedman M et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J. Clin. Invest. 94(2), 623-630 (1994).
28. Sato K, Laham RJ, Pearlman JD et al. Efficacy of intracoronary versus intravenous FGF-2 in a pig model of chronic myocardial ischemia. Ann. Thorac. Surg. 70(6), 2113-2118 (2000).
29. Rajanayagam MA, Shou M, Thirumurti V et al. Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs. J. Am. Coll. Cardiol. 35(2), 519-526 (2000).
30. Schumacher B, Pecher P, Von Specht BU, Stegmann T. Induction of neoangiogenesis in ischemic myocardium by human growth factors: first clinical results of a new treatment of coronary heart disease. Circulation 97(7), 645-650 (1998).
31. Pecher P, Schumacher BA. Angiogenesis in ischemic human myocardium: clinical results after 3 years. Ann. Thorac. Surg. 69(5), 1414-1419 (2000).
32. Sellke FW, Laham RJ, Edelman ER, Pearlman JD, Simons M. Therapeutic angiogenesis with basic fibroblast growth factor: technique and early results. Ann. Thorac. Surg. 65(6), 1540-1544 (1998).
33. Laham RJ, Sellke FW, Edelman ER et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgery: results of a Phase I randomized, double-blind, placebo-controlled trial. Circulation 100(18), 1865-1871 (1999).
34. Ruel M, Laham RJ, Parker JA et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J. Thorac. Cardiovasc. Surg. 124(1), 28-34 (2002).
35. Laham RJ, Chronos NA, Leimbach M et al. Results of a Phase I open label dose escalation study of intracoronary and intravenous basic fibroblast growth factor (rFGF-2) in patients with severe ischemic heart disease: 6 months follow-up. J. Am. Coll. Cardiol. 35(2), 73A (2000).
36. Laham RJ, Chronos NA, Pike M et al. Intracoronary basic fibroblast growth factor (FGF-2) in patients with severe ischemic heart disease: results of a Phase I open-label dose escalation study. J. Am. Coll. Cardiol. 36(7), 2132-2139 (2000).
37. Unger EF, Goncalves L, Epstein SE et al. Effects of a single intracoronary injection of basic fibroblast growth factor in stable angina pectoris. Am. J. Cardiol. 85(12), 1414-1419 (2000).
38. Hendel RC, Henry TD, Rocha-Singh K et al. Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. Circulation 101(2), 118-121 (2000).
39. Henry TD, Rocha-Singh K, Isner JM et al. Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Am. Heart J. 142(5), 872-880 (2001).
40. Henry TD, Abraham JA. Review of preclinical and clinical results with vascular endothelial growth factors for therapeutic angiogenesis. Curr. Interv. Cardiol. Rep. 2(3), 228-241 (2000).
41. Henry T, Annex B, Azrin M, Al E. Final results of the VIVA trial of rhVEGF human therapeutic angiogenesis. Circulation 100(Suppl. I), 1-476 (1999).
42. Ferguson JJ. Meeting highlights: highlights of the 48th Scientific Sessions of the American College of Cardiology. Circulation 100(6), 570-575 (1999).
43. Henry TD, Mckendall GR, Azrin MA et al. VIVA Trial: 1 year follow-up. Circulation 102(18), II-309 (2000).
44. Laham RJ, Cohen DJ, JP C, Ho KK, Mannam A, Selke FW. Longevity of the placebo effect in patients enrolled in angiogenesis and laser myocardial revascularization trials. J. Am. Coll. Cardiol. 39(Suppl. 1), 11A (2002).
45. Kleiman NS, Califf RM: Results from late-breaking clinical trials sessions at ACCIS 2000 and ACC 2000. J. Am. Coll. Cardiol. 36(1), 310-325 (2000).
46. Simons M, Annex BH, Laham RJ et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 105(7), 788-793, (2002).
47. Laham RJ, Razaee M, Post M et al. Intracoronary and intravenous administration of basic fibroblast growth factor: myocardial and tissue distribution. Drug Metab. Dispos. 27, 821-826 (1999).
48. Yla-Herttuala S, Matin JF. Cardiovascular gene therapy. Lancet 355, 213-222 (2000).
49. Laham RJ, Simons M, Sellke F. Gene transfer for angiogenesis in coronary artery disease. Ann. Rev. Med. 52, 485-502 (2001).
50. Laham RJ, Mannam A, Post MJ, Sellke F. Gene transfer to induce angiogenesis in myocardial and limb ischemia. Expert Opin. Biol. Ther. 1(6), 985-994 (2001).
51. Khan TA, Sellke FW, Laham RJ. Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia. Gene Ther. 10(4), 285-291 (2003).
52. Lee LY, Patel SR, Hackett NR et al. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann. Thorac. Surg. 69, 14-23 (2000).
53. Giordano FJ, Ping P, McKirnan MD et al. Intracoronary gene transfer of FGF-5 increases blood flow and contractile function in an ischemic region of the heart. Nat. Med. 2, 534-539 (1996).
54. Mack CA, Patel SR, Schwartz EA et al. Biologic bypass with the use of adenovirus-mediated gene transfer of the complementary DNA for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart. J. Thorac. Cardiovasc. Surg. 115, 168-176 (1998).
55. Losordo DW, Vale PR, Symes JF et al. Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. Circulation 98, 2800-2804 (1998).
56. Symes JF, Losordo DW, Vale PR et al. Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. Ann. Thorac. Surg. 68(3), 830-836 (1999).
57. 121 cDNA. Ann. Surg. 230, 466-470 (1999 ).
58. 121 cDNA to individuals with clinically significant severe coronary artery disease. Circulation 100, 468-474 (1999).
59. Vale PR, Losordo DW, Milliken CE et al. Randomized, single-blind, placebo-controlled pilot study of catheter based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia. Circulation 103, 2138-2143 (2001).
60. Losordo DW, Vale PR, Hendel RC et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 105, 2012-2018 (2002).
61. Grines CL, Watkins MW, Helmer G et al. Angiogenic Gene Therapy Trial (AGENT) inpatients with stable angina pectoris. Circulation 105, 1291-1297 (2002).
62. Hedman M, Hartikainen J, Syvanne M. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: Phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 107(21), 2677-2683 (2003).
63. Menasche P. Myobalst-based cell transplantation. Heart failure Reviews 8, 221-227 (2003).
64. Reinecke H, Poppa V, Murry CE. Skeletal muscle cells do not differentiate into cardiomyocytes after cardiac grafting. J. Mol. Cell Cardiol. 34(2), 241-249 (2002).
65. Murry CE, Wiseman RW, Schwartz SM, Hauschka SD. Skeletal Myoblast Transplantation for Repair of Myocardial Necrosis. J. Clin. Invest. 98, 2512-2523 (1996).
66. Taylor DA, Atkins BZ, Hungspreugs P et al. Regenerating functional myocardium: improved performance after skeletal myoblast transplantation. Nat. Med. 4(8), 929-933 (1998).
67. Scorsin M, Hagege A, Vilquin JT et al. Comparison of the effects of fetal cardiomyocyte and skeletal myoblast transplantation on post infarction left ventricular function. J. Thorac. Cardiovasc. Surg. 119(6), 1169-1175 (2000).
68. Menasche P, Hagege AA, Vilquin JT et al. Autologous skeletal myoblast transplantation for severe postinfarction left ventricular dysfunction. J. Am. Coll. Cardiol. 41(7), 1078-1083 (2003).
69. Klug MG, Soonpaa MH, Koh GY, Field LJ. Genetically selected cardiomyocytes from differentiating embryonic stem cells form stable intracardiac grafts. J. Clin. Invest. 98(1), 216-224 (1996).
70. Zhang YM, Hartzell C, Narlow M et al. Stem-cell derived cardiomyocytes demonstrate arrhythmic potential. Circulation 106, 1294-1299 (2002).
71. Thompson JA, Itskovitz-Elsor J, Shapiro SS et al. Embryonic stem cell lines derived from human blastocysts. Science 282, 1145-1147 (1998).
72. Pittinger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-174 (1999).
73. Reyes M, Lund T, Lenvik T et al. Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells. Blood 98(9), 2615-2625 (2001).
74. Orlic D, Kajstura J, Chimenti S et al. Bone marrow cells regenerate infracted myocardium. Nature 410, 701-705 (2001).
75. Orlic D, Kajstura J, Chimenti S et al. Mobilized bone marrow cells repair the infracted heart, improving function and survival. Proc. Natl Acad. Sci. 98(18), 10344-10349 (2001).
76. Tomita S, Mickle DAG, Weisel RD et al. Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation. J. Thorac. Cardiovasc. Surg. 123, 1132-1140 (2002).
77. Shake JG, Gruber PJ, Baumgartner WA et al. Mesenchymal cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann. Thorac. Surg. 73, 1919-1926 (2002).
78. Fuchs S, Baffour R, Zhou YF et al. Transendocardial delivery of autologous bone marrow enhances collateral perfusion and regional function in pigs with chronic experimental myocardial ischemia. J. Am. Coll. Cardiol. 37(6), 1726-1732 (2001).
79. Kamihata H, Matsubara H, Nishiue T et al. Implantation of bone marrow mononuclear cells into ischemic myocardium enhances collateral perfusion and regional function via side supply of angioblasts, angiogenic ligands and cytokines. Circulation 104, 1046-1052 (2001).
80. Strauer BE, Brehm M, Kostering M et al. Repair of infracted myocardium by autologous intracoronary mononuclear bone marrow cell transplantation in humans. Circulation 106(15), 1913-1918 (2002).
81. Tse HF, Kwong YL, Chan JK et al. Angiogenesis in ischemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 361(9351), 47-49 (2003).
82. Bel A, Messas E, Agbulut O et al. Transplantation of autologous fresh bone marrow into infracted myocardium: a word of caution. Circulation 108, II247-II252 (2003).
83. Asahara T, Maduda H, Takahashi T et al. Bone Marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85, 221-228 (1999).
84. Asahara T, Murohara T, Sullivan A et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 275, 964-967 (1997).
85. Yin AH, Miraglia S, Zanjani ED et al. AC133 a novel marker for human hematopoietic stem and progenitor cells. Blood 90, 5002-5012 (1997).
86. Nieda M, Nicol A, Denning KP et al. Endothelial cell precursors are normal components of human unbilical cord blood. Br. J. Haematol. 98, 775-777 (1997).
87. Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone marrow derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat. Med. 7, 430-436 (2001).
88. Kawamoto A, Gwon HC, Iwaguro H et al. Therapeutic potential of ex vivo expanded endothelial progenitor cells for myocardial ischemia. Circulation 103(5), 634-637 (2001).
89. Jackson KA, Majka SM, Wang H et al. Regeneration of ischemic cardiac muscle and vascular endothelium by adult stem cells. J. Clin. Invest. 107(11), 1395-1402 (2001).
90. Moore MAS, Hattori K, Heissig B et al. Mobilization of Endothelial and hematopoietic stem and progenitor cells by adenovector-mediated elevation of serum levels of SDF-1, VEGF and angiopoietin-1. Ann. NY Acad. Sci. 938, 36-45 (2001).
91. Assmus B, Schachinger V, Teupe C et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 106(24), 3009-3017 (2002).
92. Britten MB, Abolmaali ND, Assmus B et al. Infarct remodeling after intracoronary progenitor cell treatment in patients with acute myocardial infarction (TOPCARE-AMI): mechanistic insights from serial contrast-enhanced magnetic resonance imaging. Circulation 108(18), 2212-2218 (2003).
93. Rivard A, Silver M, Chen D et al. Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am. J. Pathol. 154(2), 355-363 (1999).
94. Couffinhal T, Silver M, Kearney M et al. Impaired collateral vessel development associated with reduced expression of vascular endothelial growth factor in ApoE-/-mice. Circulation 99(24), 3188-3198 (1999).
95. Simons M, Bonow RO, Chronos NA et al. Clinical trials in coronary angiogenesis: issues, problems, consensus. An expert panel summary. Circulation 102(11), E73-E86 (2000).
96. Ruel M, Wu GF, Khan TA et al. Inhibited angiogenic response to surgical FGF-2 protein therapy in a swine model of endothelial dysfunction. Circulation. 108(Suppl. 1), II335-II340 (2003).
97. Ashara T, Bauters C, Zheng LP et al. Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. Circulation 92(Suppl. 9), II365-II371 (1995).
98. Dor Y, Djonov V, Abramovich R et al. Conditional switching of VEGF provides new insights into adult neovascularization and proangiogenic therapy. EMBO J. 21(8), 1939-1947 (2002).
99. Sato K, Wu T, Laham RJ et al. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J. Am. Coll. Cardiol. 37(2), 616-623 (2001).
100. Edelman ER, Nugent MA, Karnovsky MJ. Perivascular and intravenous administration of basic fibroblast growth factor: vascular and solid organ deposition. Proc. Natl Acad. Sci. USA 90(4), 1513-1517 (1993).
101. 125I-labeled basic fibroblast growth factor (bFGF) favor intramyocardial delivery. J. Am. Coll. Cardiol. 35, 10A (2000).
102. Zhang M, Methot D, Poppa V et al. Cardiomyocyte grafting for cardiac repair: graft cell death and antideath strategies. J. Mol. Cell. Cardiol. 33, 907-921 (2001).
103. Sakakibara Y, Nishimura K, Tambara K et al. Prevascularization with gelatin microspheres containing basic fibroblast growth factor enhances the benefits of cardiomyocyte transplantation. J. Thorac. Cardiovasc. Surg. 124(1), 50-56 (2002).
104. Mangi AA, Noiseaux N, Kong D et al. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med. 9(9), 1195-1201 (2003).
105. Bel A, Messas E, Agbulut O et al. Transplantation of autologous fresh bone marrow into infarcted myocardium: a word of caution. Circulation 108, II247-II252 (2003).